Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gegen Qinlian Tang and Probiotics for Radiation Enteritis
NCT06836960Phase 2Enrolling by invitation
- Sponsor
- Jiujiang First People's Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bifidobacterium triple viable and Gegenqinlian Decoction in acute radiation enteritis (ARE) (3 arms), sponsored by Jiujiang First People's Hospital. Primary endpoints: Incidence of Acute Radiation Enteritis and Severity of Acute Radiation Enteritis. Started Jun 2025; status: enrolling by invitation.
02
Drugs
bifidobacterium triple viableGegenqinlian Decoction
03
Conditions
acute radiation enteritis (ARE)
Beyond the preview
Go deeper on NCT06836960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836960.